ArticleChinese medicine2025
Multi-omics reveals mechanism of Qi-Po-Sheng-Mai granule in reducing atrial fibrillation susceptibility in aged rats.
Article in Chinese medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Defective efferocytosis links autonomic dysfunction and atrial fibrillation: multi-omics integration andFrontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundAtrial Fibrillation (AF) is the most common arrhythmia in clinical practice, and age is an independent risk factor for the development of AF. Qi-Po-Sheng-Mai granule (QPSM) has been used clinically to treat aging-related AF, however, its underlying mechanisms remain incompletely understood.
methodsIn this study, we established a D-galactose-induced aging rat model to evaluate the effects of QPSM on aging-related AF through electrocardiograms, echocardiography, and histopathological analysis. Further, we employed transcriptomics and metabolomics to uncover molecular mechanisms and targets. Finally, in vivo experiments were conducted to validate the expression of key targets in the D-Gal-induced aging rat model and the intervention effects of QPSM.
resultsQPSM significantly reduced the susceptibility to AF in aging rats and alleviated atrial dilation and fibrosis. The combined analysis of transcriptomics and metabolomics suggested that QPSM may inhibit the occurrence of aging-related AF by modulating Nampt expression and increasing NAD
conclusionsOur study demonstrates that QPSM may reduce the susceptibility to aging-related AF by regulating Nampt expression and NAD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.